Navigation Links
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Date:2/7/2008

SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.

The Phase III trial has been designed as a global, randomized, multi-center open label trial to prospectively evaluate the safety and efficacy of Karenitecin compared to the chemotherapy drug topotecan (also known as Hycamtin(R)). Either Karenitecin or topotecan will be given intravenously daily for 5 consecutive days repeated every 3 weeks to advanced ovarian cancer patients who have previously been treated with platinum and taxane chemotherapy drugs but have become resistant to the platinum/taxane therapy. BioNumerik has received written agreement from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) regarding the clinical trial design and protocol.

Four Phase II clinical trials of intravenously administered Karenitecin have been completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced non-small cell lung cancer, and primary brain tumors. BioNumerik has also initiated a Phase I clinical trial to evaluate the safety and effectiveness of an orally administered Karenitecin formulation. Based on prior studies, BioNumerik believes Karenitecin may have the following potential advantages over currently marketed camptothecins:
-- Comparable or improved effectiveness in the treatment of certain

cancers, with a potentially improved
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, ... 7,849,611) support that prevents ankle sprains by cushioning the ... it fits securely around the outside of any shoe ... & comfort while still offering protection against sprains. With ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... validate Jennerex ... breakthrough product approach, SAN FRANCISCO and YONGIN-SI, ... Ottawa, Ontario), and its South,Korean partner Green Cross Corp., announced ... product JX-594 were published in,the premier journal Lancet Oncology. The ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") ... (NYU) School of Medicine, the Brooklyn,Hospital Center, and ... the advantages of the Company,s patented pressure cycling,technology ... week.,There were three oral presentations and four poster ...
Cached Medicine Technology:Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 2Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 3Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 4Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 4
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... and CAMBRIDGE, Mass., June 6, GlaxoSmithKline (NYSE: ... acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris),for approximately USD720 ... offer and merger of USD22.50 (or approx. GBP11.33) ... GSK has significantly enhanced its,metabolic, neurology, immunology and ...
... The makers of the WaveSense(TM),line of blood glucose ... Presto and WaveSense KeyNote Pro Blood Glucose,Monitoring Systems (BGMS). ... that consumers can buy at a value price. The ... features for increased safety., The Presto has all ...
... at the University of Cincinnati (UC), says that cases ... in the first Persian Gulf War were caused by ... meaning the exposure and illness is not as widespread ... in the July issue of Neuroepidemiology. , Ronnie Horner, ...
... CSV ) today announced that it has ... found on Carriage,s website at, http://www.carriageservices.com ., ... of Carriage,s business, operating and growth strategies,historical financial ... & Investment Profile is being published and updated ...
... part of its,ongoing efforts to alleviate human ... and Development (LIFE), recently shipped an,entire forty-foot ... Somalia., In partnership with California-based RICE ... Agency for the Horn,of Africa (ARAHA), two ...
... Grubb & Ellis,Healthcare REIT, Inc. today announced the ... of 22 office condominiums in,the Manchester-suburb of Derry, ... Professional Center consists of,approximately 70,000 square feet of ... was renovated in 1990 and again in 1996.,Nutfield ...
Cached Medicine News:Health News:New WaveSense Presto(TM) and Pro(TM) Glucose Meters to Simplify Testing 2Health News:UC research shows risk of ALS exposure in Gulf War veterans is time limited 2Health News:Carriage Services Updates Company & Investment Profile 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: